Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 205,991 | 313,747 | 127,328 | -123,756 | -18,251 |
| Depreciation Amortization | 13,553 | 55,658 | 42,152 | 28,349 | 14,405 |
| Income taxes - deferred | 9,310 | -2,198 | 24,972 | 19,374 | 9,639 |
| Accounts receivable | -110,421 | -359,963 | -544,210 | -144,347 | -7,434 |
| Accounts payable and accrued liabilities | -176,033 | 75,066 | 249,920 | 26,411 | -157,735 |
| Other Working Capital | -297,734 | -444,782 | -371,629 | -166,969 | -219,044 |
| Other Operating Activity | 425,838 | 886,552 | 831,992 | 396,354 | 258,108 |
| Operating Cash Flow | $70,504 | $524,080 | $360,525 | $35,416 | $-120,312 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -48,434 | 497,176 | 511,050 | -4,349 | 122,739 |
| PPE Investments | -21,833 | -58,697 | -35,405 | -23,263 | -8,970 |
| Purchase Of Investment | 44,725 | 0 | 0 | 0 | 0 |
| Other Investing Activity | 0 | -2,150 | -2,150 | 0 | 0 |
| Investing Cash Flow | $-25,542 | $436,329 | $473,495 | $-27,612 | $113,769 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 613,967 | 608,647 | N/A | N/A |
| Debt Repayment | N/A | -1,169,185 | -1,102,659 | N/A | N/A |
| Common Stock Issued | 13,157 | 250,028 | 208,327 | 130,587 | 49,365 |
| Other Financing Activity | 2,557 | 0 | -64,822 | -32,746 | -3,283 |
| Financing Cash Flow | $15,714 | $-305,190 | $-350,507 | $97,841 | $46,082 |
| Exchange Rate Effect | -7,064 | 34,936 | 40,637 | 41,564 | 14,058 |
| Beginning Cash Position | 1,658,807 | 968,652 | 968,652 | 968,652 | 968,652 |
| End Cash Position | 1,712,419 | 1,658,807 | 1,492,802 | 1,115,861 | 1,022,249 |
| Net Cash Flow | $53,612 | $690,155 | $524,150 | $147,209 | $53,597 |
| Free Cash Flow | |||||
| Operating Cash Flow | 70,504 | 524,080 | 360,525 | 35,416 | -120,312 |
| Capital Expenditure | -21,833 | -58,697 | -35,405 | -23,263 | -8,970 |
| Free Cash Flow | 48,671 | 465,383 | 325,120 | 12,153 | -129,282 |